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BACKGROUND. C/EBPa is a critical mediator of terminal differentiation and a tumor
suppressor through its strong antiproliferative actions on cell cycle regulatory proteins.
C/EBPa also appears to regulate androgen receptor (AR) AR signaling. There, is a paucity of
information on the expression and sub-cellular localization of C/EBPa in normal mouse and
human prostate and in prostate cancer.
METHODS. Immunohistochemistry of tissues including tissue arrays, quantitative poly-
merase chain reaction and mRNA expression database mining.
RESULTS. In the mouse prostate epithelium, C/EBPa was present at 1 week postnatal
localized in the cytosol, began to show nuclear localization at 8 weeks and continued to show
prominent nuclear expression at 10 weeks and beyond; C/EBPa mRNA was expressed at all
ages. In humans, C/EBPa showed prominent nuclear localization from peripubescence up to
middle age but was sequestered in the cytosol in older individuals; the mRNA level for C/EBPa
remained essentially unchanged. Most prostate adenocarcinomas expressed a range of levels of
C/EBPa mRNA and protein that were relatively high in metastatic tumors in a manner that
correlated with AR expression; however, most cells showed C/EBPa sequestered in the cytosol.
CONCLUSIONS. Temporal changes in sub-cellular localization of C/EBPa are consistent
with a role in prostate differentiation and as a prostate tumor suppressor; the cytoplasmic
sequestration of C/EBPa, unique to older human prostates, is arguably a permissive condition
for the greater frequency of proliferative disorders of the prostate. In malignant prostate
C/EBPa may be available to regulate AR signaling through transient changes in its sub-cellular
localization. Prostate 68: 1206–1214, 2008. # 2008 Wiley-Liss, Inc.
KEY WORDS: prostate; C/EBPa; androgen receptor
INTRODUCTION
The CCAAT enhancer binding protein (C/EBP)
family comprises at least six members, named a, b, g,
d, e, and z [1]. They are homo- or hetero-dimeric basic/
leucine zipper transcription factors that recognize the
CCAAT enhancer, a divergent dyad repeat sequence
RTTGCGYAAY, in which R and Y represent A/G and
C/T respectively [2]. Members of the C/EBP family are
required for the differentiation of adipocytes, myeloid
cells, hepatocytes and other cell types [1]. Among
C/EBP proteins, C/EBPa is distinctive in that in
addition to its transcriptional activity, it inhibits
cell proliferation by several non-genomic mechanisms
[3–5]. C/EBPa can exert its antiproliferative actions
without binding to DNA [6] through protein–protein
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interactions; they include stabilization of p21 [7,8],
disruption of E2F complexes [9–11], inhibition/
degradation of cdk2 and cdk4 [12,13] and interac-
tion with the SWI/SNF chromatin remodeling com-
plex [14].
The antiproliferative actions of C/EBPa cause it to be
a tumor suppressor in several cell types such as acute
myeloid leukemia, lung cancer, hepatoma, breast
cancer, and skin cancer [5,15–21]. However, in liver
tumors, dephosphorylation of C/EBPa by activation
of the PI3K/AKT pathway inhibits its interactions
with cdk2 and E2F complexes [22]; dephosphorylated
C/EBPa may contribute to proliferation by sequester-
ing Rb [23]. Since C/EBPa is also frequently expressed
in malignant tissues (Ref. [24] and Oncomine micro-
array data repository; http://www.oncomine.org/),
an altered phosphorylation state could be expected to
cause the protein to support tumor proliferation [23].
There is some evidence that in both humans and
rodents, C/EBPa is expressed in prostate epithelial cells
[25,26] and DNA microarray data indicates the presence
of mRNA for C/EBPa in malignant human prostate
tissue [27]. C/EBPa has also been reported to associate
with the androgen receptor (AR) [26] suggesting a role in
regulating AR signaling. Ectopic C/EBPa was anti-
proliferative in C/EBPa-negative prostate cancer cells.
Since C/EBPa could thus play a role in normal prostate
development and also in the physiology of prostate
tumors, there is currently a need for a systematic
investigation of its regulation during various stages of
the development of the normal human and mouse
prostates and in a spectrum of prostate tumors. This
study reveals unique and physiologically significant




Black/6 mice were euthanized at specific ages
ranging from 1 week to 8 months. The prostates were
dissected immediately after euthanasia and fixed in
formalin and embedded in paraffin. Sections were
stained for C/EBPausing standard procedures. Briefly,
antibody to C/EBPa (sc-61, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) was titrated on normal mouse
prostate. Rat and mouse liver were used as positive
controls. Unstained sections were microwaved for
30 sec in citrate buffer before incubation for 4 hr at
room temperature with the optimal dilution of anti-
body (2 mg/ml). A biotinolyated secondary antibody
was applied for 30 min. Specific staining was revealed
using a standard kit according to the manufacturer’s
directions (Biogenex). Normal human prostates were
obtained from autopsy and were frozen at 808C.
Frozen sections were stained as described for formalin
fixed tissue. Formalin fixed tissues were also used in the
staining of human prostates. The specificity of sc-61
antibody for C/EBPa was confirmed using HeLa cells
transfected with an expression plasmid for C/EBPa
(data not shown). In all cases, a non-immune rabbit IgG
(sc-2027, Santa Cruz Biotechnology, Inc.) (negative
control) was non-reactive.
Isolation of RNAFromMouse andHumanProstate
Prostate tissues from mice of various age groups
were dissected immediately following euthanasia
of the mice and homogenized in TRIZOL Reagent
(Invitrogen) using a TissueMiser (Fisher). Total RNA
was isolated from the tissue homogenates following the
manufacturer’s protocol for TRIZOL Reagent. Total
RNA was similarly isolated after pulverizing frozen
human prostate tissue. Control adult human liver RNA
was purchased from Ambion (Foster City, CA).
Real Time-ReverseTranscription-Polymerase
Chain Reaction (Real Time-RT-PCR)Analysis
Reverse transcription followed by quantitative real-
time PCR was used to measure the endogenous mRNA
levels for mouse or human C/EBPa and for mouse or
human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (control). Total RNA (1 mg per sample) was
reverse transcribed with random primers using
the High Capacity cDNA Reverse Transcription kit
(Applied Biosystems) according to manufacturers’
protocol. The reverse transcription product was sub-
jected to quantitative real-time PCR using the Real-
Time PCR master mix (Applied Biosystems) in the 7500
Real-Time PCR System (Applied Biosystems). Primers
and TaqMan probe for mouse and human C/EBPa
and for human GAPDH were obtained from Applied
Biosystems. The mRNA for mouse GAPDH was
measured using the Syber Green I nucleic acid gel stain
from Molecular Probes (Invitrogen detection techno-
logies). Fluorescence data generated were monitored
and recorded on a 7500 Real-Time PCR sequence
detection system (Applied Biosystems). All samples
were measured in triplicate and the values normalized
to the corresponding GAPDH values. As a negative
control, the Real Time PCR master mix was used
without any template added during the reverse tran-
scription step of the quantitative real time RT-PCR
assays. The results are presented as mean SE.
TissueArrayAnalysis
Replicate prostate normal and cancer tissue
array slides (#PR802, #PR952, and #BC19111) were
purchased from US Biomax, Inc. (Rockville, MD). The
arrays were probed with primary rabbit antibody to
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Fig. 1. ExpressionandlocalizationofC/EBPa in themouseprostateepitheliumduringdevelopment.A:Uniformstainingof thecytoplasmof
the prostate epithelium already present at1week of age.B: Diffuse staining of the cytoplasm of the prostate epithelium at 3 weeks of age.
C:Highermagnificationof theprostateof a3-week-oldmouse.Note thecompletelackofnuclear staining.D:Diffusestainingof thecytoplasm
onlyintheepitheliumstillpresentat6weeks.E:Diffusestainingof theprostaticepitheliumincludingsomenuclearstainingat8weeks.F:Diffuse
cytoplasmic andprominentnuclear stainingin theprostatic epitheliumof a10-week-oldmouse.G:Diffuse cytoplasmic andnuclear staining at
16weeksof age.H:Uniformstainingof the cytoplasmandnucleiin8-month-oldmouse.I:Highermagnificationofprostate of an8-month-old
mouse demonstrates cytoplasmic andprominentnuclear staining in theprostatic epithelium. [Color figure canbeviewed in the online issue,
whichis availableatwww.interscience.wiley.com.]
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either C/EBPa (SC-61, Santa Cruz Biotechnology, Inc.)
or to AR (SC-816, Santa Cruz Biotechnology, Inc.) or with
normal rabbit IgG (negative control). Antigen retrieval
was performed using Target Retrieval Solution (S1699)
from DAKO. Sections were incubated for 30 min with
ready-to-use (2.5%) normal horse blocking serum. They
were then incubated with primary antibodies (2 mg/ml)
for 1h at room temperature. After washing, the slides
were incubated for 30 min with ImPRESS Reagent
(peroxidase conjugated anti-rabbit IgG, MP7407 from
Vector Laboratories). The sections were then washed
and incubated for 5 min with peroxidase substrate
(DAB, K3466 from DAKO Cytomation). After rinsing
with tap water, the slides were counterstained with
Hematoxilin QS (H-3404, Vector Laboratories). A
duplicate set of slides were treated as above but without
counterstaining. Twenty times object images were
scanned for each slide.
RESULTS
Expression of C/EBPaDuring the
Developmentof theMouse Prostate
The temporal sequence of C/EBPa expression in
the developing mouse prostate was examined by
immunohistochemical staining (Fig. 1). C/EBPa was
expressed throughout the cytoplasm of the prostate
epithelial cells as early as 1 week; cytoplasmic expres-
sion remained strong and diffuse up to 6 weeks of age.
At 8 weeks of age, C/EBPa was expressed diffusely in
both the cytoplasm and in most nuclei of the prostate
epithelium; strong, uniform expression of C/EBPa in
both the cytoplasm and nuclei of the prostate epithelium
persisted at 16 weeks. By 8 months, expression of
C/EBPa was still diffuse in the cytoplasm and prom-
inent but not complete in the nuclei. The expression of
C/EBPa in the liver of the adult mouse remained
relatively high and was also nuclear (data not shown).
The mRNA level for C/EBPa remained relatively
constant throughout the development of the mouse
prostate (1–12 weeks) and was significantly lower
(1/30) compared to the level of C/EBPamRNA in the
adult mouse liver (Fig. 2); this may be at least partially
accounted for by the fact that there is a greater
proportion of C/EBPa-negative interstitial tissue in
the prostate. The C/EBPa mRNA decreased modestly
in older (6 months and over) mice (Fig. 2).
Expression of C/EBPa in the
NormalHuman Prostate
Figure 3 shows representative examples of the
expression of C/EBPa in the normal human prostate.
The Prostate
Fig. 2. Quantitative analysis of C/EBPa mRNA expression in
the developing mouse prostate.The amount of mRNA for mouse
C/EBPawasdeterminedfromatleast twomicefromeachagegroup
byreal timeRT-PCRandnormalized to the correspondingvalue for
GAPDH. The values are represented as the fraction of C/EBPa
mRNAfromanadultmouseliver. [Color figure canbeviewedin the
onlineissue,whichis availableatwww.interscience.wiley.com.]
Fig. 3. Expression and localization of C/EBPa in the human
prostate epithelium in relation to age.A:Diffusenuclear and cyto-
plasmic stainingof theprostateepitheliumat16yearsof age.Intense
nuclear and cytoplasmic staining is maintained at 27 (B) and
29 (C) years of age (D) Prominent but not diffuse expression of
C/EBPa in the nucleus and diffuse staining in the cytoplasm of
prostate epithelium in a 49-year-old male. E: Consistent cyto-
plasmic expression and occasional nuclear staining for C/EBPa at
51 years of age. F: C/EBPa is present in the cytoplasm but not in
the nuclei of a 59-year-oldman. [Color figure can be viewed in the
onlineissue,whichis availableatwww.interscience.wiley.com.]
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There was strong diffuse staining of C/EBPa in the
nucleus and cytoplasm of prostate epithelial cells at
16 years of age (peri-pubescent). Nuclear and cyto-
plasmic expression of C/EBPa remained unchanged at
27 and 29 years of age. By 49 years of age, there was
some decline in nuclear expression of C/EBPa. Loss
of nuclear staining became widespread by age 59, with
C/EBPa expression observed in the cytoplasm. Cyto-
solic localization of C/EBPa in the prostates of older
men, noted in Figure 3, was further established by data
that included tissue array analysis of normal prostate
(Table I).
The mRNA for C/EBPa was expressed in human
prostate at a relatively higher level than mouse
prostate, when measured in relation to liver (30% of
liver C/EBPa mRNA) (Fig. 4); again, it may be noted
that like the mouse prostate, the human prostate has a
greater proportion of C/EBPa-negative interstitial
tissue than liver.
Expression of C/EBPa in ProstateAdenocarcinoma
The expression of C/EBPa in prostate adeno-
carcinoma was examined together with that of AR by
immunohistochemical analysis of a tumor tissue
array containing diseased tissue from 78 patients. The
patients ranged in age from 38 to 87 years and the tumor
samples covered the entire range of tumor grade and
Gleason scores. The signal intensities for both C/EBPa
and AR were scored in arbitrary units in the range of
0 (absent) through 4 (highest). Representative results
of for the staining of C/EBPa and AR together with
negative controls are shown in Figure 5. C/EBPa
expression in the tumors was predominantly in the
cytosol although some cells in the sections showed
nuclear staining. A box plot analysis of the results
showed that samples with higher AR scores (3 and 4)
co-expressed significantly higher levels of C/EBPa
(Fig. 6A). However, there was no significant correlation
between the Gleason score and the expression level of
either C/EBPa or AR (data plot not shown).
To examine the relative mRNA levels for C/EBPa
and AR in prostate adenocarcinoma samples from
a large number of patients, DNA microarray data
was mined from the largest single study of prostate
tumors [27] through the Oncomine repository at: http://




tion%20of%20prostate%20cancer. The box plot in
Figure 6B shows an elevation in the mRNA for C/EBPa
in prostate tumors relative to normal prostate. The box
plot in Figure 6C indicates a significant elevation in
AR mRNA in the more aggressive prostate tumors
compared to non-aggressive tumors. Among the
aggressive tumors, there was a significant positive
correlation between the expression level of AR and that
of C/EBPa (r¼ 0.5111471) (Fig. 6D), consistent with
immunohistochemical studies of tumor tissue arrays
discussed above.
DISCUSSION
C/EBPa gene knockout mice have been reported to
die within hours after birth from hypoglycemia due to
The Prostate
TABLE I. Subcellular Localization of C/EBPa in the
Prostate Epithelia ofOlderMen
Sample No. Age (years) Sub-cellular localization
1 52 Focal nuclear/cytosolic
2 52 Focal nuclear/cytosolic
3 52 Focal nuclear/cytosolic
4 62 Cytosolic












17 77 Cytosolic/focal nuclear
18 77 Cytosolic/focal nuclear
19 77 Cytosolic
Fig. 4. Quantitative analysis of C/EBPamRNAexpression in the
humanprostate inrelation to age.The amountofmRNAforhuman
C/EBPawasdeterminedbyreal timeRT-PCRandnormalizedto the
corresponding value for GAPDH. The values are represented as
the fraction of C/EBPa mRNA from an adult human liver. [Color
figure can be viewed in the online issue, which is available atwww.
interscience.wiley.com.]
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decreases in glycogen synthase and gluconeogenic
enzymes in the liver [28]. This period precedes
the time of maturation of the prostate but the
expression of C/EBPa in the prostate suggests a role
for it in prostate physiology. This study reveals features
of C/EBPa expression that are distinctive in the normal
human prostate in comparison to other normal human
tissues or to the normal mouse prostate. The mouse
prostate shows expression of C/EBPa protein and
mRNA expression very early in its development but the
protein is localized in the nuclear compartment, which
is the site of its action, only at the onset of terminal
differentiation; C/EBPa expression persists in the
nuclear compartment in older mice. In the human
prostate also, C/EBPa protein and mRNA expression
was observed at all ages that were examined (from
peri-pubescence through the 8th decade); however
the protein was progressively sequestered in the
cytosolic compartment in older men, in contrast to
observations in the liver of older men [29] and adipose
tissue in post-menopausal women [24], where C/EBPa
occurred in the nucleus. It thus appears that in normal
The Prostate
Fig. 5. Scoring of AR andC/EBPa expression in humanprostate tumors.A:þ1nuclear expression of AR.B:þ2 nuclear expression of AR.
C:þ3 nuclear expression of AR.D:þ4 nuclear expression of AR.E:þ2 nuclear and cytoplasmic expression of AR.F: No expression of AR.
G:þ1cytoplasmic expressionofC/EBPa.H:þ2 cytoplasmic expressionofC/EBPa.I:þ3 cytoplasmic expressionofC/EBPa.J:þ4 cytoplasmic
expressionofC/EBPa.K:þ2nuclearandcytoplasmicexpressionofC/EBPa.L:NoexpressionofC/EBPa.[Color figurecanbeviewedintheonline
issue,whichis availableatwww.interscience.wiley.com.]
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prostate tissues, C/EBPa is regulated through modu-
lation of its intracellular localization. The temporal
sequence of expression and nuclear import of C/EBPa
is entirely consistent with a role in prostate dif-
ferentiation since the nucleus, rather than the cytosol,
is the known site of most if not all of the biological
actions of C/EBPa, particularly its strong antiproli-
ferative actions. It is also reasonable to suggest then,
that the age-related sequestration of the protein in the
cytosol of the prostate epithelium may contribute
significantly to the permissive state of the human
prostate to the relatively high frequency of proliferative
disorders in older males [30].
In contrast to other tumor suppressors, C/EBPa
was frequently highly expressed in prostate tumors.
Here again, the largely cytosolic localization of the
protein would account for its inability to exert its
antiproliferative effect. A similar, largely cytosolic
localization was reported for C/EBPa in epithelial
ovarian tumors [24]. In malignant tissues, however, the
continued expression of C/EBPa may reflect a long-
term role for the protein. Notably, a small fraction of the
tumor cells did show the protein localized in the
nucleus at any given time, indicating that some of the
transcriptional activities of the protein may be utilized
by the proliferating cells at the appropriate times by
regulating its nuclear-cytoplasmic shuttling. Indeed
nuclear-cytoplasmic shuttling of major transcription
factors, including members of the C/EBP family, is
known to be regulated through signaling pathways
[31,32]. The specific proliferative versus antiprolifer-
ative role of C/EBPa may be controlled by regulating
nuclear-cytoplasmic transport in relation to cellular
contexts such as the cell cycle stage. In this regard, a
significant observation is the frequent co-expression of
C/EBPa with AR in prostate cancer, particularly in the
The Prostate
Fig. 6. Expression ofC/EBPa andARprotein andmRNAinprostate tumors.PanelA: Immunohistochemical analysis of a prostate tumor
tissue array for co-expression of AR and C/EBPa; scores in arbitrary units for the expression of C/EBPa and AR in a microarray containing
78tumorspecimens,determinedasdescribedunderMaterialsandMethodsSection,aregraphedasaboxplot.PanelB:Boxplotof theexpres-
sion of C/EBPamRNA in prostate tumors retrieved from theOncomineDNAmicroarray database.Panel C: Box plot of the expression of
ARmRNA in prostate tumors retrieved from the same Oncomine DNAmicroarray data set as in panel B.Panel D: Scatter plot for the
co-expression ofC/EBPa andARmRNAsrepresentedin themetastatic prostate tumorgroup in Panels B andC. [Color figure canbeviewed
in theonlineissue,whichis availableatwww.interscience.wiley.com.]
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more aggressive/metastatic tumors. AR signaling is
critical for the physiology of most prostate tumors even
when the tumors are hormone refractory [33]. It has
recently been reported that C/EBPa can physically
associate with AR and influence gene transcription by
AR, although the impact of this interaction on global
gene expression profiles is yet to be analyzed [26]. The
co-expression of the two interacting proteins, which
are both major regulators of transcription, strongly
suggests a combined role for them in determining the
molecular phenotype of prostate tumors.
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